Galecto Corp - Aset Bersih saben Siji Saham GLTO

Galecto, Inc. (GLTO) drug development for cancer and fibrosis remains independent of macroeconomic trends, as confirmed by the key book value metric on GURU.Markets, where the current level is approximately 4.98. High scaling potential through contract synthesis enables the company to capture global markets. The business is currently focusing on clinical trials of innovative galectin inhibitors to combat tissue scarring.

Galecto Inc (GLTO): Nilai Buku Saham saka 04.07.2022 nganti 10.03.2026

galecto.com - rincian analitis lan metrik utama (GLTO)

- rega lan prakiraan konsensus rega:

Kutipan saham Galecto Corp|GLTO - Rega prakiraan analis

- data kapitalisasi pasar:

Nilai pasar Galecto, Inc.|GLTO - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Galecto|GLTO - Nilai Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku galecto.com|GLTO - Nilai Agregat Aset

- data utang lan likuiditas:

Total Utang marang Modal Galecto, Inc.|GLTO - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Galecto|GLTO - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Galecto, Inc.

Pambiji fundamental perusahaan:Galecto Corp - GLTO

This indicator determines the intrinsic value of the business by measuring the residual capital per share after the full settlement of all liabilities. By analyzing the trend of the book value per share, an investor assesses the actual asset backing of Galecto, Inc. (GLTO), which is critical during cost optimization and while awaiting results for the GB1211 drug for liver cancer therapy.

Pesaing Galecto, Inc. (GLTO)